STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLLS
  4. [6-K] Cellectis S.A. Current Report (Foreign Issuer)

Cellectis to release Q2 2026 results August 6

Cellectis S.A., a clinical-stage biotechnology company focused on gene-edited cell and gene therapies, stated it will report second quarter 2026 financial results for the quarter ended June 30, 2026 on Thursday, August 6, 2026 after the close of the US market.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Cellectis S.A., a clinical-stage biotechnology company focused on gene-edited cell and gene therapies, stated it will report second quarter 2026 financial results for the quarter ended June 30, 2026 on Thursday, August 6, 2026 after the close of the US market.

The company indicated it will not host a conference call for these results and directed investors to its website and investor relations contacts for the press release and any questions. Cellectis uses an allogeneic approach to CAR T immunotherapies and is listed on Nasdaq and Euronext Growth.

Positive

  • None.

Negative

  • None.
Date of report July 30, 2026 Date of the company’s Form 6-K report
Q2 2026 quarter end June 30, 2026 Quarter end date for which Cellectis will report results
Results release date August 6, 2026 Date Cellectis will release Q2 2026 financial results after US market close
Form 6-K regulatory
"Form 6-K report of foreign private issuer"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
foreign private issuer regulatory
"Report of foreign private issuer pursuant to Rule 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
allogeneic approach medical
"The company utilizes an allogeneic approach for CAR T immunotherapies"
CAR T immunotherapies medical
"An allogeneic approach for CAR T immunotherapies in oncology"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Cellectis (CLLS) release its Q2 2026 financial results?
Cellectis will release its Q2 2026 financial results on Thursday, August 6, 2026 after the close of the US market. The results cover the company’s second quarter and will be detailed in a press release available to investors.

Will Cellectis (CLLS) hold a conference call for its Q2 2026 results?
Cellectis stated it will not host a conference call to discuss its Q2 2026 results. Instead, investors are directed to the company’s website and investor relations contacts for the press release and any follow-up questions.

What reporting period will Cellectis (CLLS) Q2 2026 results cover?
The Q2 2026 results from Cellectis will cover the quarter ending June 30, 2026. This corresponds to the company’s financial performance for the second quarter of 2026, which will be summarized in the upcoming earnings press release.

Where can investors access the Cellectis (CLLS) Q2 2026 earnings press release?
The Q2 2026 earnings press release will be available in the Investors section of Cellectis’ website, under press releases. Investors can visit https://www.cellectis.com/en/investors/press-releases/ to review the detailed financial information once published.

What kind of company is Cellectis (CLLS) and where is it listed?
Cellectis is a clinical-stage biotechnology company using gene-editing to develop cell and gene therapies, including allogeneic CAR T treatments. It is listed on the Nasdaq Global Market under CLLS and on Euronext Growth under ALCLS.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: July 30, 2026

Commission File Number: 001-36891

Cellectis S.A.
(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

 

 

EXHIBIT INDEX

 

Exhibit Title
   
99.1 Press Release dated July 30, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Cellectis S.A.    
  (Registrant)
   
  
Date: July 30, 2026     /s/ André Choulika    
  André Choulika
  Chief Executive Officer
  

EXHIBIT 99.1

Cellectis to Report Second Quarter Financial Results on August 6, 2026

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2026 ending June 30, 2026 on Thursday, August 6, 2026 after the close of the US market.

The press release will be available in the Investors section of Cellectis’ website: https://www.cellectis.com/en/investors/press-releases/

Cellectis will not host a conference call to discuss these results. Our investor relations team remains available for questions at investors@cellectis.com

About Cellectis

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.

Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.

For further information on Cellectis, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment

  • Q2 2026 announcement PR_ENGLISH (https://ml.globenewswire.com/Resource/Download/f560a55d-b231-4ae6-b032-b17f8846ec16)

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases

Keep reading

More on CLLS

Trending in the feed

Open the live feed